CSF3 and infection: No significant differences were observed in infection-related mortality between patients who received primary prophylaxis with G-CSF and those who did not, with non-significant heterogeneity (RR, 0.96 [95% CI, 0.71–1.30], p = 0.80; I2 = 0%, p = 0.50) (Fig. 2a).